Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome

Chou, Shuli; Zhang, Shiqing; Guo, Huating; Chang, Yung-Fu; Zhao, Wenjing; Mou, Xiangyu

doi:10.3389/fmicb.2022.879207

Cited by 13 publications

(8 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, gut-brain studies may benefit from also investigating the virome along with the microbiome [33]. A road worth pursuing may be the investigation of narrow-spectrum antibiotic substances made by plants and microorganisms and targeted microbiome modulation by peptides or phage therapy for the treatment of affective disorders [60 ▪ ,61 ▪ ].…”

Section: Discussionmentioning

confidence: 99%

Advances in the gut microbiome and mood disorders

Mörkl

Butler

Lackner

2023

Current Opinion in Psychiatry

View full text Add to dashboard Cite

Purpose of reviewThe gut microbiome is in constant bidirectional communication with the brain through the microbiota-gutbrain-axis. Mood disorders are among the most common psychiatric disorders and include major depressive disorder and bipolar disorder. The gut microbiome is altered in individuals with mood disorders and has a role in its inflammatory pathophysiology. In this article, we performed a narrative review of clinical studies, randomized controlled trials and meta-analyses addressing advances in gut microbiome research in mood disorders and included articles that were published between 2021 and 2022. Recent findingsStudies highlight transdiagnostic alterations of microbiota in mood disorders, with reductions of butyrateproducing bacteria. Participants with major depressive disorder showed altered beta-diversity, while participants with bipolar disorder showed reduced alpha-diversity. Both disorders exhibit alterations in the metabolome. Early pilot studies addressed the possibility of using the gut microbiome for the prediction of treatment response and the blood microbiome for the diagnosis of psychiatric disorders. Findings from clinical trials support the use of probiotics as an add-on therapy for major depressive disorder. The second published case report in the literature reported a favourable outcome of a patient with bipolar disorder after faecal microbiota transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Advances in the gut microbiome and mood disorders

Mörkl

Butler

Lackner

2023

Current Opinion in Psychiatry

View full text Add to dashboard Cite

show abstract

“…Among the metabolites released by the intestinal host, AMPs have the potential to modulate and maintain the stability of the intestinal microbiota. [208] However, there are still certain limitations that persist in the progress and utilization of AMPs. These include challenges related to the extraction of such peptides from organisms and the significant expenses TA B L E  AMPs against F. nucleatum and F. nucleatum biofilms.…”

Section:  Ampsmentioning

confidence: 99%

Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges

Liu,

Yu,

Dong

et al. 2023

Exploration

View full text Add to dashboard Cite

Colorectal cancer (CRC) is generally characterized by a high prevalence of Fusobacterium nucleatum (F. nucleatum), a spindle‐shaped, Gram‐negative anaerobe pathogen derived from the oral cavity. This tumor‐resident microorganism has been closely correlated with the occurrence, progression, chemoresistance and immunosuppressive microenvironment of CRC. Furthermore, F. nucleatum can specifically colonize CRC tissues through adhesion on its surface, forming biofilms that are highly resistant to commonly used antibiotics. Accordingly, it is crucial to develop efficacious non‐antibiotic approaches to eradicate F. nucleatum and its biofilms for CRC treatment. In recent years, various antimicrobial strategies, such as natural extracts, inorganic chemicals, organic chemicals, polymers, inorganic‐organic hybrid materials, bacteriophages, probiotics, and vaccines, have been proposed to combat F. nucleatum and F. nucleatum biofilms. This review summarizes the latest advancements in anti‐F. nucleatum research, elucidates the antimicrobial mechanisms employed by these systems, and discusses the benefits and drawbacks of each antimicrobial technology. Additionally, this review also provides an outlook on the antimicrobial specificity, potential clinical implications, challenges, and future improvements of these antimicrobial strategies in the treatment of CRC.

show abstract

“…In addition, the GI tract, ultimately relating to the whole digestive system from mouth to anus, carries a very high microbial biomass which simplifies microbiome-targeted analyses for technical reasons including a beneficial ‘signal-to-noise’ ratio. 48–50 Finally, the GI microbiome appears to be manipulable through antibiotic therapy, 51 52 diet, 53 oral bacterial supplementation, 54 or FMT, 35 which all may offer straightforward prospects for ICI-resensitizing interventions. 32 …”

Section: Compartmentalization Of the Host Microbiomementioning

confidence: 99%

Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects

Boesch

Horvath

Baty

et al. 2022

J Immunother Cancer

View full text Add to dashboard Cite

The host microbiome is polymorphic, compartmentalized, and composed of distinctive tissue microbiomes. While research in the field of cancer immunotherapy has provided an improved understanding of the interaction with the gastrointestinal microbiome, the significance of the tumor-associated microbiome has only recently been grasped. This article provides a state-of-the-art review about the tumor-associated microbiome and sheds light on how local tumor microbiota shapes anticancer immunity and influences checkpoint immunotherapy outcome. The direct route of interaction between cancer cells, immune cells, and microbiota in the tumor microenvironment is emphasized and advocates a focus on the tumor-associated microbiome in addition to the spatially separated gut compartment. Since the mechanisms underlying checkpoint immunotherapy modulation by tumor-associated microbiota remain largely elusive, future research should dissect the pathways involved and outline strategies to therapeutically modulate microbes and their products within the tumor microenvironment. A more detailed knowledge about the mechanisms governing the composition and functional quality of the tumor microbiome will improve cancer immunotherapy and advance precision medicine for solid tumors.

show abstract

Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome

Cited by 13 publications

References 112 publications

Advances in the gut microbiome and mood disorders

Advances in the gut microbiome and mood disorders

Emerging strategies for combating Fusobacterium nucleatum in colorectal cancer treatment: Systematic review, improvements and future challenges

Compartmentalization of the host microbiome: how tumor microbiota shapes checkpoint immunotherapy outcome and offers therapeutic prospects

Contact Info

Product

Resources

About